multichem ia plus
abbott laboratories d.o.o. koranska 2 10000 zagreb -
extavia
novartis europharm limited - interferon beta-lb - multipla skleroza - Иммуностимуляторы, - extavia indiciran za liječenje:pacijenti s jedinim demijelinizacijske događaj pri aktivnom воспалительном procesu, ako je to tako ozbiljno, da se osigura obrada s внутривенным uvođenjem kortikosteroida, ako alternativne dijagnoze su isključeni, i ako su oni odlučili biti visok rizik za razvoj klinički određenog multiple skleroze;u bolesnika s ремиттирующим multiplom sklerozom, a dva ili više pogoršanja u posljednje dvije godine;bolesnika sa sekundarno-прогрессирующим multiple skleroze s aktivnom obliku, o tome svjedoče recidiva.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
gilenya
novartis europharm limited - финголимод hidroklorid - multipla skleroza - imunosupresivi - gilenya je navedeno kao jedan bolesti дорабатывая terapije kod visoke aktivnosti relapsing ublažavanje multiplom sklerozom za sljedećih skupina odraslih pacijenata i pedijatrijska bolesnika u dobi od 10 godina i stariji:pacijenti sa visokom aktivnošću bolesti, unatoč potpun i adekvatan tretman sa najmanje jednim bolest дорабатывая terapije (za iznimke i informacija o вымыванию razdoblja vidi 4. 4 i 5. orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.
fingolimod mylan
mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1)orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.
dimethyl fumarate mylan
mylan ireland limited - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
fingolimod mylan
mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
mayzent
novartis europharm limited - siponimod фумаровая kiselina - multipla skleroza, Рецидивно-Ремиттирующее - selektivni imunosupresivi - mayzent indiciran za liječenje odraslih bolesnika sa sekundarno-прогрессирующим multiplom sklerozom (ВПРС) s aktivnim bolesti svjedoče recidiva ili značajke za vizualizaciju aktivnosti upalnog procesa.
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multipli mijelom - antineoplastična sredstva - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
jayempi
nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.